Bifidobacterium longumBifidobacterium longum NBM 7-1 strain of the present invention, liver diseases can be effectively prevented, alleviated and treated.
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A23K 10/16 - Ajout de micro-organismes ou de leurs produits d’extraction, p. ex. de protéines provenant d’organismes unicellulaires, à des compositions de produits alimentaires
2.
MEDIUM COMPOSITION FOR SELECTIVELY CULTURING LACTOBACILLUS PLANTARUM AND USE THEREOF
C12Q 1/04 - Détermination de la présence ou du type de micro-organismeEmploi de milieux sélectifs pour tester des antibiotiques ou des bactéricidesCompositions à cet effet contenant un indicateur chimique
C12N 1/38 - Stimulation chimique de la croissance ou de l'activité par addition de composés chimiques qui ne sont pas des facteurs essentiels de croissanceStimulation de la croissance par élimination d'un composé chimique
Lactobacillus fermentumLactobacillus fermentum SRK414 strain which has accession number KCTC13687BP. The strain of the present invention is excellent in reducing barrier permeability and reducing amyloid beta and tau proteins and has an excellent effect in improving cognitive function, and accordingly, the strain can be useful for a food and therapeutic agent for same purposes.
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
Lactobacillus delbrueckiilactislactis strain as an active ingredient. The present invention provides a composition for preventing, alleviating or treating cognitive impairment or Alzheimer's disease (AD), comprising a Lactobacillus delbrueckii subsp. lactis strain as an active ingredient. The strain of the present invention has the excellent effects of reducing amyloid beta protein (Aβ) or tau protein (Tau) and improving cognitive function, and thus can be effectively used as a composition for preventing, alleviating or treating cognitive impairment or AD.
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
5.
LACTOBACILLUS DELBRUECKII SUBSP. LACTIS CKDB001 STRAIN, AND COMPOSITION FOR PREVENTION, AMELIORATION, OR TREATMENT OF NON-ALCOHOLIC FATTY LIVER COMPRISING SAME
The present invention relates to a Lactobacillus lactis CKDB001 strain, and a composition for the prevention or treatment of non-alcoholic fatty liver comprising same. When the composition of the present invention is ingested, the composition has the effect of ameliorating high-fat diet-induced fatty cirrhosis and inflammations caused thereby, and thus the composition of the present invention can be effectively used as a preparation for ameliorating or treating non-alcoholic fatty cirrhosis and steatohepatitis.
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
6.
PHARMACEUTICAL COMPOSITION COMPRISING NEW LACTOBACILLUS PLANTARUM KC3 STRAIN AND LEONURUS JAPONICUS EXTRACT AS ACTIVE INGREDIENTS FOR PREVENTING OR TREATING RESPIRATORY DISEASE AND USE THEREOF
Disclosed are a pharmaceutical composition for preventing or treating a respiratory disease, and health functional food, a food composition, and a quasi-drug composition for preventing and ameliorating a respiratory disease, each including, as active ingredients, a Lactobacillus plantarum KC3 strain and a Leonurus japonicus extract. The composition including the Lactobacillus plantarum KC3 strain (Accession No: KCTC13375BP) and the Leonurus japonicus extract as active ingredients according to an aspect has a defense effect against respiratory damage caused by air pollutants such as fine dust and can inhibit expression of IL-17A, TNF-α, and CXCL-1, thereby being able to effectively treat or prevent a respiratory disease including chronic obstructive pulmonary disease (COPD). In addition, the effect of the active ingredient combination above results in a synergistic inhibition or treatment effect on bronchial inflammation by the administration compared to the existing therapeutic effect of a respiratory inflammatory disease of each of the Leonurus japonicus extract and the lactic acid bacteria KC3. Thus, the present disclosure can be usefully utilized for the prevention or treatment of a respiratory disease.
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
COMPOSITION USING NOVEL LACTOBACILLUS PLANTARUM KC3 STRAIN FOR PREVENTION OR TREATMENT OF IMMUNE IMPAIRMENT, RESPIRATORY INFLAMMATORY DISEASE, ALLERGY, AND ASTHMA AND USE THEREOF
The present disclosure relates to a composition for ameliorating immune disorders and preventing or treating respiratory inflammatory diseases, the composition including, as an active ingredient, new lactic acid bacteria from Lactobacillus plantarum KC3 (also referred to as “CKDB-KC3”). It is confirmed that the composition is useful as a pharmaceutical composition or a health functional food for ameliorating immune disorders and preventing and treating a respiratory inflammatory diseases by confirming that the new strain of the present disclosure exhibits excellent activities of ameliorating immune disorders and inhibiting respiratory inflammatory diseases through the following animal experiments: an experiment on the characteristics of the new lactic acid bacteria from the Lactobacillus plantarum KC3 (see Experimental Example 1); an experiment on the inhibitory effect of probiotics on the expression of inflammatory cytokines in the intestines (see Experimental Example 2); an experiment on the anti-inflammatory effect on ear edema (see Experimental Example 3); and an experiment on the defense effect against respiratory damage caused by air pollutants such as fine dust (see Experimental Example 4 and FIG. 1). That is, the new strain disclosed herein may be usefully utilized as a pharmaceutical composition, health functional food, or health supplement food for the amelioration of immune disorders and the prevention or treatment of respiratory inflammatory diseases.
PHARMACEUTICAL COMPOSITION COMPRISING NOVEL LACTOBACILLUS PLANTARUM KC3 STRAIN AND LEONURUS JAPONICUS EXTRACT AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF RESPIRATORY DISEASE AND METHOD USING SAME
Leonurus japonicusLeonurus japonicus extract as active ingredients according to an aspect exhibits a defensive effect against a respiratory damage caused by air pollutants, such as fine dust, etc., and can inhibit the expression of IL-17A, TNF-α, and CXCL-1, and as such, can effectively treat or prevent respiratory diseases including chronic obstructive pulmonary disease (COPD). In addition, the effect of the combination is synergistic for inhibiting or treating bronchial inflammation, compared to the respective therapeutic effects on respiratory inflammatory diseases upon administration of the Leonurus japonicus extract and the Lactobacillus bacteria KC3.
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
9.
LACTOBACILLUS DELBRUECKII SUBSP. LACTIS CKDB001 STRAIN, AND COMPOSITION FOR PREVENTION, AMELIORATION, OR TREATMENT OF NON-ALCOHOLIC FATTY LIVER COMPRISING SAME
The present invention relates to a Lactobacillus lactis CKDB001 strain, and a composition for the prevention or treatment of non-alcoholic fatty liver comprising same. When the composition of the present invention is ingested, the composition has the effect of ameliorating high-fat diet-induced fatty cirrhosis and inflammations caused thereby, and thus the composition of the present invention can be effectively used as a preparation for ameliorating or treating non-alcoholic fatty cirrhosis and steatohepatitis.
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (République de Corée)
Inventeur(s)
Huh, Chul Sung
Park, Hyunjoon
Yeo, Soyoung
Choi, In-Suk
Kim, Byoung-Kook
Chu, Jaeryang
Abrégé
Lactobacillus rhamnosusLactobacillus rhamnosus LDTM7511 strain (Accession No: KCTC 18735P) and a composition for the prevention, amelioration, or treatment of inflammatory bowel disease, the composition comprising same as an active ingredient. It has been experimentally confirmed that the Lactobacillus rhamnosus LDTM7511 strain of the present invention has resistance to an intestinal stress environment as probiotics, and has antibacterial and anti-inflammatory activities, and thus can be effectively used to prevent, ameliorate, or treat inflammatory bowel disease.
The present invention relates to a method for preparing a crystalline form A of P1, P4-di(uridine 5'-)tetraphosphate sodium salt tetrahydrate and a crystalline form A of P1, P4-di(uridine 5'-)tetraphosphate sodium salt tetrahydrate prepared thereby, wherein the crystalline form A of P1, P4-di(uridine 5'-)tetraphosphate sodium salt tetrahydrate maintains a moisture content of about 5.0 to 11.0 wt%, and thus has been proved to be a novel crystalline form different from conventional crystalline forms. According to the method of the present invention, the crystalline form A of P1, P4-di(uridine 5'-)tetraphosphate sodium salt tetrahydrate can be conveniently and stably prepared without the use of a process unsuitable for mass production and a separate apparatus, and thus the crystalline form A can be mass-produced more efficiently.
COMPOSITION USING NOVEL LACTOBACILLUS PLANTARUM KC3 STRAIN FOR PREVENTION OR TREATMENT OF IMMUNE IMPAIRMENT, RESPIRATORY INFLAMMATORY DISEASE, ALLERGY, AND ASTHMA AND USE THEREOF
The present invention relates to a composition comprising a novel lactic acid bacterium Lactobacillus plantarum KC3 (also referred to as "CKDB-KC3") as an active ingredient for alleviation of immune impairment and for prevention or treatment of a respiratory inflammatory disease. The novel strain Lactobacillus plantarum KC3 according to the present invention was found to have excellent activity of alleviating immune impairment and inhibiting a respiratory inflammatory disease as measured through animal experiments including an experiment for characteristics of the novel Lactobacillus plantarum KC3 strain (experimental example 1); an inhibitory effect of probiotics on the expression of bowel inflammatory cytokines (experimental example 2); a test for anti-inflammatory inhibitory effect on ear edema (experimental example 3); a protective effect on respiratory tract injury caused by air pollutants such as fine dust, etc. (experimental example 4, figure 1), etc. The composition was observed to be available as a pharmaceutical composition or health functional food for alleviation of immune impairment or for prevention and treatment of a respiratory inflammatory disease and as such, finds advantageous applications in a pharmaceutical composition, a health functional food, or a health supplemental food for alleviation of immune impairment and for prevention or treatment of a respiratory inflammatory disease.
KONKUK UNIVERSITY INDUSTRIAL COOPERATION CORP (République de Corée)
CKD BIO CORP (République de Corée)
Inventeur(s)
Yun, Hyung Don
Choi, In Suk
Jeon, Hyun Woo
Abrégé
The present invention relates to a method for enzymatically producing beta amino acids by using a novel ester hydrolase, and more specifically, to a method whereby the productivity of a beta-amino acid can be increased by using a novel ester hydrolase (lipase/esterase) when synthesizing a beta-keto acid from a beta-keto ester during the process of synthesizing the beta-amino acid.
The present invention relates to a method for improving lactic acid bacteria in survival rate, storage stability, resistance to acid or bile, and adherence to intestinal epithelial cells by coating the surface of lactic acid bacteria with silk fibroin, and a lactic acid bacteria composition prepared therethrough. Conventional techniques construct only a physical protective barrier outside a lactic acid bacteria body by multi-stage coating and thus retain the limitation of being unable to identify an effect on the coherence of lactic acid bacteria to intestinal epithelial cells upon the uptake of the lactic acid bacteria. In contrast, the present invention provides a method in which lactic acid bacteria is coated with silk fibroin extracted from cocoons, whereby the lactic acid bacteria is improved in stability under a storage and distribution condition as well as having remarkably increased stability and intestinal adherence particularly under an intestinal environment.
The present invention relates to a composition for preventing, ameliorating, or treating non-alcoholic fatty liver disease comprising Lactobacillus helveticus and Bifidobacterium strains. Since taking the composition of the present invention has the effect of ameliorating fatty liver disease and inflammation caused by a high fat diet, the composition of the present invention can be effectively used as a preparation for ameliorating or treating non-alcoholic steatosis and steatohepatitis.
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
16.
NOVEL METHOD FOR PRODUCING PERAMIVIR TRIHYDRATE, AND WATER-BASED DRYING THEREOF
The present invention relates to a method for producing peramivir trihydrate, which is an inhibitor of neuraminidase infection, as an anti-influenza agent. According to the production method of the present invention, peramivir trihydrate can be produced with high yield and stability through a process suitable for producing excellent pharmaceuticals and quality control standards (GMP) without using highly-toxic methanol and activated carbon.
C07C 277/08 - Préparation de la guanidine ou de ses dérivés, c.-à-d. de composés contenant le groupe les atomes d'azote liés par des liaisons simples ne faisant pas partie de groupes nitro ou nitroso de guanidines substituées
C07C 279/16 - Dérivés de la guanidine, c.-à-d. composés contenant le groupe les atomes d'azote liés par des liaisons simples ne faisant pas partie de groupes nitro ou nitroso ayant des atomes d'azote de groupes guanidine liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceuticals; pharmaceutical preparations containing
botulinum toxin; pharmaceutical preparations for cosmetic
purposes; pharmacological preparations for skin care;
medicated lotions; pharmaceutical agents for epidermis;
injectable dermal fillers; gel for activating tissue for
medical use; pharmaceutical preparations for cramp;
preparations for the treatment of myodystonia; muscle
relaxants; preparations for the treatment of hyperhidrosis;
pharmaceutical preparations for the treatment of headache;
pharmaceutical preparations for the treatment of pain;
hemorrhoid preparations; preparations for the treatment of
psychiatric disorders; preparations for the treatment of
nervous disorder; pharmaceutical agents affecting sensory
organs; ophthalmic preparations; medicines for dental
purposes; pharmaceutical preparations for use in
dermatology; pharmaceutical preparations for orthopaedic
purposes; pharmaceutical agents affecting digestive organs;
pharmaceutical preparations for urogenital organs;
pharmaceutical preparations for the treatment of physical
disorder; pharmaceutical preparations for chemical disorder
treatment; cultures of microorganisms for medical use.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceuticals; pharmaceutical preparations containing
botulinum toxin; pharmaceutical preparations for cosmetic
purposes; pharmacological preparations for skin care;
medicated lotions; pharmaceutical agents for epidermis;
injectable dermal fillers; gel for activating tissue for
medical use; pharmaceutical preparations for cramp;
preparations for the treatment of myodystonia; muscle
relaxants; preparations for the treatment of hyperhidrosis;
pharmaceutical preparations for the treatment of headache;
pharmaceutical preparations for the treatment of pain;
hemorrhoid preparations; preparations for the treatment of
psychiatric disorders; preparations for the treatment of
nervous disorder; pharmaceutical agents affecting sensory
organs; ophthalmic preparations; medicines for dental
purposes; pharmaceutical preparations for use in
dermatology; pharmaceutical preparations for orthopaedic
purposes; pharmaceutical agents affecting digestive organs;
pharmaceutical preparations for urogenital organs;
pharmaceutical preparations for the treatment of physical
disorder; pharmaceutical preparations for chemical disorder
treatment; cultures of microorganisms for medical use.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceuticals; pharmaceutical preparations containing
botulinum toxin; pharmaceutical preparations for cosmetic
purposes; pharmacological preparations for skin care;
medicated lotions; pharmaceutical agents for epidermis;
injectable dermal fillers; medicated tissue augmenting gel;
pharmaceutical preparations for cramp; preparations for the
treatment of myodystonia; muscle relaxants; preparations for
the treatment of hyperhidrosis; headache treatment
preparations; pain treatment preparations; hemorrhoid
preparations; preparations for the treatment of psychiatric
disorders; preparations for the treatment of nervous
disorder; pharmaceutical agents affecting sensory organs;
ophthalmic preparations; medicines for dental purposes;
pharmaceutical preparations for use in dermatology;
pharmaceutical preparations for orthopaedic purposes;
pharmaceutical agents affecting digestive organs;
pharmaceutical preparations for urogenital organs;
pharmaceutical preparations for physical disorder treatment;
pharmaceutical preparations for chemical disorder treatment;
cultures of microorganisms for medical or veterinary use.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; Pharmaceutical preparations containing botulinum toxin for medical use for use in aesthetic procedures, namely, the treatment of wrinkles; Pharmaceutical preparations for treating and preventing skin diseases; Pharmaceutical preparations for the treatment of skin irritations, namely bee stings, sunburn, rashes, sores, corns, calluses, and acne, Pharmaceutical preparations for the treatment of blackheads, Pharmaceutical preparations for hydrating the skin during pregnancy; Medicated lotions, namely, acne medications, Medicated after-shave lotions, Medicated lotions, namely, medicated body moisturizers, Medicated diaper rash lotions, Medicated lotions for sunburn; Pharmaceutical agents for treating physically caused lesions, Pharmaceutical agents for epidermis, namely, topical anti-inflammatories; Injectable dermal fillers; Medicated acne pre-moistened wipes, Antibacterial wipes for medical and veterinary purposes; Pharmaceutical preparations for treating leg cramps, Pharmaceutical preparations, namely, menstrual symptom treatment preparations; Pharmaceutical preparations for the treatment of movement disorders, namely, myodystonia; Muscle relaxants; Preparations for the treatment of hyperhidrosis; Headache treatment preparations; Pain treatment preparations; Hemorrhoid preparations; Pharmaceutical preparations for the treatment of psychiatric disorders, namely, mood disorders, cognitive disorders, schizophrenia and bipolar disorders; Pharmaceutical preparations for the treatment of anxiety disorders; Pharmaceutical agents affecting sensory organs, namely, nose drops for medical purposes; Ophthalmic preparations; Antibiotics for dental use; Pharmaceutical preparations for use in dermatology, namely, hydrocortisone skin creams and antimicrobials for dermatological use; Pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders, Pharmaceutical preparations for orthopaedic purposes, namely, muscle relaxants; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, namely infertility, sexually transmitted diseases, incontinence and sexual dysfunction; Pharmaceutical preparations for treating physically caused lesions; Pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, Pharmaceutical preparations for the treatment of brain diseases and disorders, namely, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, multiple sclerosis, Pharmaceutical preparations for the treatment of diseases and disorders caused by chemical exposure, namely, pharmaceutical preparations for the treatment of respiratory diseases and disorders, for ophthalmological use and for the prevention and treatment of cancer; Cultures of microorganisms for medical use for the treatment of gastrointestinal disorders, immune health, iron absorption disorders and bone health, Cultures of microorganisms for medical use, namely, probiotic cultures for dietetic and nutritional supplement purposes, Cultures of microorganisms for use as an ingredient in the manufacture of dietary supplements, food supplements, vitamin and mineral preparations.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceuticals for treating dermatological disease and conditions; pharmaceutical preparations containing botulinum toxin for treating skin wrinkles; pharmaceutical preparations for cosmetic purposes for treating skin wrinkles; pharmacological preparations for skin care; medicated lotions for the skin; pharmaceutical agents for epidermis; injectable dermal fillers; pharmaceutical gel for activating tissue for medical use for the treatment of dermatological conditions; pharmaceutical preparations for cramps; pharmaceutical preparations for the treatment of myodystonia; muscle relaxants; pharmaceutical preparations for the treatment of hyperhidrosis; pharmaceutical preparations for the treatment of headache; pharmaceutical preparations for the treatment of pain; hemorrhoid preparations; pharmaceutical preparations for the treatment of psychiatric disorders; pharmaceutical preparations for the treatment of nervous disorder; pharmaceutical agents affecting sensory organs; ophthalmic preparations; medicines for dental purposes; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for orthopaedic purposes; pharmaceutical agents affecting digestive organs; pharmaceutical preparations for urogenital organs; pharmaceutical preparations for the treatment of respiratory disorders; pharmaceutical preparations for chemical disorder treatment; cultures of microorganisms for medical use
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; Pharmaceutical preparations containing botulinum toxin for medical use for use in aesthetic procedures, namely, the treatment of wrinkles; Pharmaceutical preparations for treating and preventing skin diseases; Pharmaceutical preparations for the treatment of skin irritations, namely bee stings, sunburn, rashes, sores, corns, calluses, and acne, Pharmaceutical preparations for the treatment of blackheads, Pharmaceutical preparations for hydrating the skin during pregnancy; Medicated lotions, namely, acne medications, Medicated after-shave lotions, Medicated lotions, namely, medicated body moisturizers, Medicated diaper rash lotions, Medicated lotions for sunburn; Pharmaceutical agents for treating physically caused lesions, Pharmaceutical agents for epidermis, namely, topical anti-inflammatories; Injectable dermal fillers; Medicated acne pre-moistened wipes, Antibacterial wipes for medical and veterinary purposes; Pharmaceutical preparations for treating leg cramps, Pharmaceutical preparations, namely, menstrual symptom treatment preparations; Pharmaceutical preparations for the treatment of movement disorders, namely, myodystonia; Muscle relaxants; Preparations for the treatment of hyperhidrosis; Headache treatment preparations; Pain treatment preparations; Hemorrhoid preparations; Pharmaceutical preparations for the treatment of psychiatric disorders, namely, mood disorders, cognitive disorders, schizophrenia and bipolar disorders; Pharmaceutical preparations for the treatment of anxiety disorders; Pharmaceutical agents affecting sensory organs, namely, nose drops for medical purposes; Ophthalmic preparations; Antibiotics for dental use; Pharmaceutical preparations for use in dermatology, namely, hydrocortisone skin creams and antimicrobials for dermatological use; Pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders, Pharmaceutical preparations for orthopaedic purposes, namely, muscle relaxants; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, namely infertility, sexually transmitted diseases, incontinence and sexual dysfunction; Pharmaceutical preparations for treating physically caused lesions; Pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, Pharmaceutical preparations for the treatment of brain diseases and disorders, namely, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, multiple sclerosis, Pharmaceutical preparations for the treatment of diseases and disorders caused by chemical exposure, namely, pharmaceutical preparations for the treatment of respiratory diseases and disorders, for ophthalmological use and for the prevention and treatment of cancer; Cultures of microorganisms for medical use for the treatment of gastrointestinal disorders, immune health, iron absorption disorders and bone health, Cultures of microorganisms for medical use, namely, probiotic cultures for dietetic and nutritional supplement purposes, Cultures of microorganisms for use as an ingredient in the manufacture of dietary supplements, food supplements, vitamin and mineral preparations.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceuticals for treating dermatological disease and conditions; pharmaceutical preparations containing botulinum toxin for treating skin wrinkles; pharmaceutical preparations for cosmetic purposes for treating skin wrinkles; pharmacological preparations for skin care; medicated lotions for the skin; pharmaceutical agents for epidermis; injectable dermal fillers; pharmaceutical gel for activating tissue for medical use for the treatment of dermatological conditions; pharmaceutical preparations for cramps; pharmaceutical preparations for the treatment of myodystonia; muscle relaxants; pharmaceutical preparations for the treatment of hyperhidrosis; pharmaceutical preparations for the treatment of headache; pharmaceutical preparations for the treatment of pain; hemorrhoid preparations; pharmaceutical preparations for the treatment of psychiatric disorders; pharmaceutical preparations for the treatment of nervous disorder; pharmaceutical agents affecting sensory organs; ophthalmic preparations; medicines for dental purposes; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for orthopaedic purposes; pharmaceutical agents affecting digestive organs; pharmaceutical preparations for urogenital organs; pharmaceutical preparations for the treatment of respiratory disorders; pharmaceutical preparations for chemical disorder treatment; cultures of microorganisms for medical use
24.
METHOD OF PRODUCING BETA OR GAMMA AMINO ACIDS USING GLUTAMIC ACID REGENERATION REACTION
KONKUK UNIVERSITY INDUSTRIAL COOPERATION CORP (République de Corée)
CKD BIO CORP (République de Corée)
Inventeur(s)
Choi, In Suk
Yun, Hyung Don
Kim, Geon Hee
Jeon, Hyun Woo
Abrégé
The present invention relates to a method of producing beta or gamma amino acids using a glutamic acid regeneration reaction. The present invention can induce the production of high concentrations of beta and gamma amino acids by using glutamic acid as an amino donor, and the present invention can increase productivity by removing an inhibitory effect of by-products that may be problematic in a conventional reaction. In addition, the present invention uses a cheaper amino donor, and thus is advantageous in the price competitiveness of a product and also can overcome the inhibitory effect on the product through optimization of reaction conditions.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceuticals for treating dermatological diseases and conditions; pharmaceutical preparations containing botulinum toxin for treating skin wrinkles; pharmaceutical preparations for cosmetic purposes for treating skin wrinkles; pharmacological preparations for skin care; medicated lotions for the skin; pharmaceutical agents for epidermis; injectable dermal fillers; medicated tissue augmenting gel for the treatment of dermatological conditions; pharmaceutical preparations for cramps; pharmaceutical preparations for the treatment of myodystonia; muscle relaxants; pharmaceutical preparations for the treatment of hyperhidrosis; headache treatment preparations; pain treatment preparations; hemorrhoid preparations; pharmaceutical preparations for the treatment of psychiatric disorders; pharmaceutical preparations for the treatment of nervous disorder; pharmaceutical agents affecting sensory organs; ophthalmic preparations; medicines for dental purposes; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for orthopaedic purposes; pharmaceutical agents affecting digestive organs; pharmaceutical preparations for urogenital organs; pharmaceutical preparations for treatment of respiratory disorder; pharmaceutical preparations for chemical disorder treatment; cultures of microorganisms for medical or veterinary use
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; Pharmaceutical preparations containing botulinum toxin; Pharmaceutical preparations for treating and preventing skin diseases; Pharmaceutical preparations for the treatment of skin irritations, namely bee stings, sunburn, rashes, sores, corns, calluses, and acne, Pharmaceutical preparations for the treatment of blackheads, Pharmaceutical preparations for hydrating the skin during pregnancy; Medicated lotions, namely, acne medications, Medicated after-shave lotions, Medicated lotions, namely, medicated body moisturizers, Medicated diaper rash lotions, Medicated lotions for sunburn; Pharmaceutical agents for treating physically caused lesions, Pharmaceutical agents for epidermis, namely, topical anti-inflammatories; Injectable dermal fillers; Medicated acne pre-moistened wipes, Antibacterial wipes for medical and veterinary purposes; Pharmaceutical preparations for treating leg cramps, Pharmaceutical preparations, namely, menstrual symptom treatment preparations; Pharmaceutical preparations for the treatment of movement disorders, namely, myodystonia; Muscle relaxants; Preparations for the treatment of hyperhidrosis; Headache treatment preparations; Pain treatment preparations; Hemorrhoid preparations; Pharmaceutical preparations for the treatment of psychiatric disorders, namely, mood disorders, cognitive disorders, schizophrenia and bipolar disorders; Pharmaceutical preparations for the treatment of anxiety disorders; Pharmaceutical agents affecting sensory organs, namely, nose drops for medical purposes; Ophthalmic preparations; Antibiotics for dental use; Pharmaceutical preparations for use in dermatology, namely, hydrocortisone skin creams and antimicrobials for dermatological use; Pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders, Pharmaceutical preparations for orthopaedic purposes, namely, muscle relaxants; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, namely infertility, sexually transmitted diseases, incontinence and sexual dysfunction; Pharmaceutical preparations for treating physically caused lesions; Pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, Pharmaceutical preparations for the treatment of brain diseases and disorders, namely, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, multiple sclerosis, Pharmaceutical preparations for the treatment of diseases and disorders caused by chemical exposure, namely, pharmaceutical preparations for the treatment of respiratory diseases and disorders, for ophthalmological use and for the prevention and treatment of cancer; Cultures of microorganisms for medical and veterinary use for the treatment of gastrointestinal disorders, immune health, iron absorption disorders and bone health, Cultures of microorganisms for medical and veterinary use, namely, probiotic cultures for dietetic and nutritional supplement purposes, Cultures of microorganisms for use as an ingredient in the manufacture of dietary supplements, food supplements, vitamin and mineral preparations.
27.
COMPOSITION FOR PREVENTING OR TREATING SECONDARY OSTEOPOROSIS COMPRISING PROBIOTICS AS ACTIVE INGREDIENT
KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (République de Corée)
Inventeur(s)
Lee, Inock
Park, Nahyun
Kim, Byoung-Kook
Lee, Chulsang
Kim, Saehun
Choi, In Suk
Abrégé
Lactobacillus plantarumLactobacillus plantarum A41 strain with accession number KCTC13686BP, and pharmaceutical and food compositions comprising, as an active ingredient, the strain or a culture thereof. The strain according to the present invention and the culture thereof have an excellent effect in preventing, alleviating, or treating osteoporosis, particularly secondary osteoporosis, and thus can be usefully employed in food and pharmaceutical compositions for said purpose.
KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (République de Corée)
Inventeur(s)
Lee, Inock
Park, Nahyun
Kim, Byoung-Kook
Lee, Chulsang
Kim, Saehun
Choi, In Suk
Abrégé
Lactobacillus fermentumLactobacillus fermentum SRK414 strain with accession number KCTC13687BP, and pharmaceutical and food compositions comprising, as an active ingredient, the strain or a culture thereof. The strain according to the present invention and the culture thereof have an excellent effect in preventing, alleviating, or treating osteoporosis, particularly secondary osteoporosis, and thus can be usefully employed in food and pharmaceutical compositions for said purpose.
Lactobacillus bulgaricusLactobacillus helveticusLactobacillus plantarumBifidobacterium bifidumBifidobacterium bifidum CKDB001 (Accession Number: KCTC13114BP), which are novel isolated lactic acid strains, or a mixed strain thereof, has an excellent effect of reducing intestinal cell inflammation caused by alcoholic irritation, and can thus be usefully used as food or a therapeutic agent for preventing or alleviating alcoholic intestinal injury.
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
30.
COMPOSITION COMPRISING LACTIC ACID BACTERIA IMPROVED IN INTESTINAL ADHERENCE BY COATING WITH SILK FIBROIN
The present invention relates to a method for improving lactic acid bacteria in survival rate, storage stability, resistance to acid or bile, and adherence to intestinal epithelial cells by coating the surface of lactic acid bacteria with silk fibroin, and a lactic acid bacteria composition prepared therethrough. Conventional techniques construct only a physical protective barrier outside a lactic acid bacteria body by multi-stage coating and thus retain the limitation of being unable to identify an effect on the coherence of lactic acid bacteria to intestinal epithelial cells upon the uptake of the lactic acid bacteria. In contrast, the present invention provides a method in which lactic acid bacteria is coated with silk fibroin extracted from cocoons, whereby the lactic acid bacteria is improved in stability under a storage and distribution condition as well as having remarkably increased stability and intestinal adherence particularly under an intestinal environment.
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61K 35/744 - Bactéries lactiques, p. ex. entérocoques, pédiocoques, lactocoques, streptocoques ou leuconostoques
A23K 10/18 - Ajout de micro-organismes ou de leurs produits d’extraction, p. ex. de protéines provenant d’organismes unicellulaires, à des compositions de produits alimentaires de micro-organismes vivants
C12N 1/38 - Stimulation chimique de la croissance ou de l'activité par addition de composés chimiques qui ne sont pas des facteurs essentiels de croissanceStimulation de la croissance par élimination d'un composé chimique
A61K 35/00 - Préparations médicinales contenant des substances ou leurs produits de réaction de constitution non déterminée
31.
METHOD FOR INCREASING SURVIVAL RATE, STORAGE STABILITY, ACID RESISTANCE OR BILE RESISTANCE OF LACTIC ACID BACTERIUM
The present invention provides: a method for increasing the survival rate, storage stability, acid resistance and bile resistance of a lactic acid bacterium after freeze drying of the lactic acid bacterium by adding proline during culturing of the lactic acid bacterium or after culturing the lactic acid bacterium; and a lactic acid bacterium produced by means of the method. In the method of the present invention, a protective agent such as proline is incorporated in high concentration in a lactic acid bacterial body, thereby not only increasing the stability of the lactic acid bacteria themselves to external environmental stresses such as freeze-drying stability and storage stability but also markedly improving the acid resistance and bile resistance which are markers of stability in the environment of the intestinal tract during lactic acid bacterium ingestion. Prior art techniques are poorly economically competitive and have limited industrial use since these techniques involve the use of complex methods of constructing a physical protective barrier on the outside of the lactic acid bacterial body by multi-step coating such as double coating, triple coating and quadruple coating of proteins, polysaccharides, porous polymers, edible oils and fats or the like thereon, whereas the present invention involves an economical method which greatly increases the resistance of the lactic acid bacterial body itself to external physicochemical stresses and increases the survival rate of same during gastrointestinal transit, and allows the inherent functionality of the lactic acid bacterium to be exhibited in the intestines and can overcome the problem of elevated cost that results from existing multi-step coating processes.
The present invention provides a method for producing daptomycin comprising a step of culturing by adding, to a culture medium of a Streptomyces sp. Strain, decanoyl glyceride as a material of an n-decanoyl side chain. The method for producing daptomycin of the present invention adds decanoyl glyceride as a material of an n-decanoyl side chain, and thus is free of the problem of microbial cell growth inhibition that occurs when decanoic acid is directly added. The method for producing daptomycin of the present invention can add decanoyl glyceride as a material of an n-decanoyl side chain in a high concentration, and thus exhibits significantly increased daptomycin productivity. The present invention provides daptomycin produced by the method of the present invention and a composition for preparing daptomycin comprising Streptomyces sp. CKDBD 1100 strain (KCTC 12558BP) and decanoyl glyceride. The method of the present invention uses decanoyl glyceride as a precursor in daptomycin fermentation, and thus significantly increases daptomycin productivity compared to the case of using decanoic acid or natural oil containing numerous impurities other than decanoic acid; further simplifies the purification process by significantly reducing related substances, and enables the production of high purity daptomycin while improving the yield.
C12P 21/04 - Peptides ou polypeptides cycliques ou pontés, p. ex. bacitracine
C12P 1/04 - Préparation de composés ou de compositions, non prévue dans les groupes , utilisant des micro-organismes ou des enzymesProcédés généraux de préparation de composés ou de compositions utilisant des micro-organismes ou des enzymes utilisant des bactéries
The present invention relates to a method for preparing 1-deoxy-1-(2-hydroxyethyl amino)-D-glucitol from D-glucitol by using a borohydride complex as a reducing agent, and to a method for preparing miglitol from the 1-deoxy-1-(2-hydroxyethyl amino)-D-glucitol. The present invention has valuable use in the preparation of miglitol which is a therapeutic agent for diabetes.
C07C 215/12 - Composés contenant des groupes amino et hydroxy liés au même squelette carboné ayant des groupes hydroxy et des groupes amino liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant saturé et acyclique l'atome d'azote du groupe amino étant de plus lié à des groupes hydrocarbonés substitués par des groupes hydroxy
A61K 31/133 - Amines, p. ex. amantadine ayant des groupes hydroxyle, p. ex. sphingosine
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
34.
NOVEL CKDBM 0901 STRAIN OF GLUCONOBACTER SPECIES HAVING OUTSTANDING YIELD IN BIOCONVERSION TO 6-HYDROXY-ETHYL AMINO-L-SORBOSE
The present invention relates to: a strain of the Gluconobacter species which is resistant to 1-hydroxyethyl amino-D-sorbitol, and is able to bioconvert 1-hydroxyethyl amino-D-sorbitol into 6-hydroxyethyl amino-L-sorbose in high yield; and a use therefor. The present invention can advantageously be used for the production of miglitol precursors and miglitol.
C12N 1/38 - Stimulation chimique de la croissance ou de l'activité par addition de composés chimiques qui ne sont pas des facteurs essentiels de croissanceStimulation de la croissance par élimination d'un composé chimique
35.
PROCESS FOR PREPARING CASPOFUNGIN AND NOVEL INTERMEDIATES THEREOF
The present invention relates to a novel process for preparing the aza cyclohexapeptide compound 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0 (caspofungin), which can improve the problem due to a pungent odor and toxicity during the process and can prepare caspofungin as a final product at high yield compared to conventional processes, and to novel intermediates which are used in the preparation process.
The present invention relates to an improved method of manufacturing mycophenolate mofetil. More particularly, the present invention relates to a method of manufacturing mycophenolate mofetil with high purity comprising : a)converting mycophenolate to an amine salt by reacting with an amine base; and b)reacting the resultant with a halogenating agent and 2-morpholinoethanol continuously.
C07D 405/06 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 307/88 - Benzo [c] furannesBenzo [c] furannes hydrogénés avec un atome d'oxygène lié directement en position 1 ou 3
